From 7 weeks to 3 hours. A 97% reduction.
How Regeneron brought scientific content creation in-house — and unlocked seven-figure savings in the process.
7 wks → 3 hrs
Average time to approved content
97%
Reduction in production time
+30%
More content creators enabled
Background
A world-class science team, constrained by a slow content machine
Regeneron is one of the most scientifically distinguished biopharmaceutical companies in the world — with a pipeline of medicines built on rigorous research and a Commercial team responsible for communicating complex clinical and economic outcomes to payers, physicians, and healthcare decision-makers. But in 2024, a critical bottleneck was undermining that commercial capability. The process of turning scientific insight into polished, approved presentations and videos was taking an average of seven weeks — driven by heavy reliance on external agencies and protracted internal approval cycles. In a market that moves fast, seven weeks is a competitive liability.
The Challenge
Seven weeks between insight and audience — in a market that doesn't wait
Agency dependency at scale
Regeneron's Commercial teams relied heavily on external agencies to produce clinical and economic outcome presentations and videos. The cost was significant — both in direct agency fees and in the opportunity cost of weeks spent briefing, iterating, and waiting for final assets.
Time-sensitive insights going unused
Market updates, competitive intelligence, and clinical data readouts have a short window of commercial relevance. At seven weeks per asset, many insights were stale before they reached their audience — or simply never got made at all.
A small pool of content creators
The expertise and tooling required to produce high-quality scientific content was concentrated in a narrow group of people. The broader Commercial team — closer to the market and the customer — was largely excluded from the creation process.
Value-based content falling short
As payers and healthcare systems increasingly demand economic evidence alongside clinical data, Regeneron needed a faster, more flexible way to produce value-based presentations that could be tailored to specific audiences and updated in real time.
The Solution
VarsaAI: bringing content creation back in-house, at speed
Regeneron partnered with VarsaAI in 2024, initially deploying the platform with its Commercial teams for one specific and high-priority use case: rapid creation of value-based presentations and videos that communicate clinical and economic outcomes to healthcare decision-makers. The initial use case was chosen deliberately. Value-based content sits at the intersection of scientific complexity and commercial urgency — demanding clinical accuracy, visual polish, and the flexibility to be quickly tailored for different payer audiences.
Commercial teams onboarded as content creators
VarsaAI's pharma-native platform enabled Commercial team members — without design or production skills — to build scientifically accurate presentations and videos directly, working from existing data and approved content libraries.
Scientific content generated from data — not from scratch
Clinical outcomes data, health economic models, and published evidence could be transformed into structured, audience-appropriate presentations within hours — with VarsaAI's life-sciences-trained AI handling structure, language, and visual logic.
Agency workflows replaced with internal capability
By shifting standard content production in-house, Regeneron dramatically reduced its dependence on external agency relationships for routine commercial materials — freeing agency budget for genuinely complex, high-value creative work.
Speed-to-market as a competitive capability
With content production measured in hours rather than weeks, Regeneron's Commercial teams gained the ability to respond rapidly to market developments — producing updated payer materials, competitive response decks, and congress follow-up content at the pace the market actually moves.
The Time Transformation
From 2 months to 3 hours — a 97% reduction in production time
Before VarsaAI
7 weeks
Average concept-to-approved asset
With VarsaAI
3 hours
Average concept-to-approved asset
Results
Seven-figure savings. Thirty percent more creators. One platform.
7-Figure
Annual Savings in Agency Fees
Regeneron has achieved seven-figure annual savings by bringing content production in-house with VarsaAI, dramatically reducing external agency spend on standard commercial materials.
97%
Reduction in Production Time
From an average of 7 weeks to 3 hours per asset — a 97% reduction in the time between concept and approved, distribution-ready content.
+30%
More Content Creators
30% more of the Commercial team is now enabled to create content directly — bringing market-close insight into the production process for the first time.
Hours
Not Weeks — Time-Sensitive Content, Captured
Market updates, competitive intelligence, and clinical data readouts that previously went unused can now be turned into commercial assets within hours of becoming available.
"Two months to three hours. That's not an incremental improvement — that's a fundamentally different way of working. We can now respond to the market in real time, and our Commercial team has been transformed from content consumers into content creators."
— Regeneron Commercial Team · VarsaAI Customer, 2024
The Bigger Picture
It's been a game changer.
The shift from agency-dependent production to in-house AI-powered creation has not just saved Regeneron money — it has changed what the Commercial team is capable of. Content that once required weeks of external resource, multiple briefing rounds, and significant budget is now produced internally, in hours, by the people closest to the science and the market.
Why It Worked
Purpose-built for pharma — not adapted from something else
The critical factor in Regeneron's success with VarsaAI was domain specificity. General-purpose AI content tools require significant manual effort to produce scientifically credible pharma content — they don't understand clinical terminology, health economic frameworks, or the specific requirements of payer-facing materials. VarsaAI was built exclusively for pharma and life sciences. Its AI understands the language and structure of clinical outcomes communication, enabling Commercial teams to produce scientifically accurate, visually polished content without the need for specialist production skills or external agency support.
"VarsaAI didn't just make us faster. It made us capable of things we simply couldn't do before — responding to market events in real time, enabling our whole Commercial team to create, and redirecting significant budget away from routine production and towards genuine strategy."
— Regeneron Commercial Team · VarsaAI Customer, 2024
See what VarsaAI can do for your team
Book a 20-minute demonstration